Table 2 Effects of non-alcoholic fatty liver disease and prognostic factors on progression-free survival after Immune checkpoint inhibitor therapy in univariate and multivariate Cox regression models
Parameter | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
Gender | ||||
Male | Reference | |||
Female | 1.072 (0.735—1.563) | 0.719 | ||
Age | ||||
< 65 | Reference | |||
≥ 65 | 1.116 (0.866—1.437) | 0.397 | ||
Body mass index (kg/m2)* | ||||
< Median | Reference | |||
≥ Median | 0.867 (0.617—1.218) | 0.410 | ||
ECOG performance status | ||||
0 | Reference | Reference | ||
≥ 1 | 1.477 (1.144—1.906) | 0.003 | 1.336 (1.033—1.728) | 0.027 |
Diabetes | ||||
No | Reference | |||
Yes | 1.395 (0.934—2.082) | 0.104 | ||
Hypertension | ||||
No | Reference | |||
Yes | 0.947 (0.718—1.248) | 0.698 | ||
Smoking | ||||
No | Reference | |||
Yes | 0.844 (0.655—1.087) | 0.189 | ||
Hyperlipidemia | ||||
No | Reference | |||
Yes | 0.947 (0.718—1.248) | 0.698 | ||
Total bilirubin | 1.001 (0.976—1.027) | 0.924 | ||
Albumin/Globulin ratio | 0.582 (0.385—0.881) | 0.011 | 0.628 (0.397—0.994) | 0.047 |
lactic dehydrogenase | 1.002 (1.001—1.003) | 0.001 | 1.001 (1.000—1.002) | 0.037 |
Hemoglobin (g/L) | 0.989 (0.981—0.996) | 0.004 | 0.994 (0.986—1.002) | 0.138 |
Blood urea nitrogen | 0.935 (0.867—1.008) | 0.079 | 0.924 (0.858—0.995) | 0.035 |
Serum creatinine | 0.996 (0.987—1.004) | 0.325 | ||
Pathological types | ||||
adenocarcinoma | Reference | |||
squamous carcinoma | 0.782 (0.602—1.015) | 0.064 | ||
other | 0.673 (0.380—1.193) | 0.176 | ||
Types of ICIs | ||||
PD-1 antibody | Reference | |||
PD-L1 antibody | 1.195 (0.756—1.889) | 0.445 | ||
Stages | ||||
Stage III | Reference | Reference | ||
Stage IV | 2.062 (1.490—2.852) | < 0.001 | 2.037 (1.461—2.840) | < 0.001 |
Groups | ||||
Non-NAFLD | Reference | |||
NAFLD | 0.959 (0.713—1.292) | 0.785 | ||